US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Gene Editing

424.17

-8.5521-1.98%

Number of Gainers:- -

Number of Losers:4

Number of Flat:- -

PE:- -

High:430.89

Open:430.89

Low:421.32

Close:432.49

Volume:593.51K

Turnover:9.14M

Market Cap:9.57B

Float Cap:8.97B

Loading ...

Intellia Therapeutics appoints Jing Marantz as chief medical officer

Intellia Therapeutics Appoints Jing L. Marantz, M.d., Ph.d., as Chief Medical Officer

THOMSON REUTERS

Press Release: Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer

Beam Therapeutics Reports Initial Phase 1/2 Data for BEAM-301 in Glycogen Storage Disease Type Ia Trial

Crispr Therapeutics General Counsel James R. Kasinger Disposes of 1,990 Common Shares Worth $119,481.19

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026

Editas wins approval to launch EDIT-401 Strive trial

Editas Medicine Receives Approval in Australia for Phase 3 Trial of EDIT-401 to Treat Hyperlipidemia

MT Newswires Live

Editas Medicine receives approval to initiate clinical trial of EDIT-401

Editas Wins Australian Clearance to Start Phase 1/2 EDIT-401 Trial in HeFH Patients

Editas Medicine - Expects Topline Safety and Efficacy Data for Edit-401 Later in 2027

THOMSON REUTERS

Editas Medicine - to Begin Patient Dosing in 2026, Report Initial Data in Q1 2027

THOMSON REUTERS

Editas Medicine Receives Approval to Initiate First-in-Human Clinical Trial of Edit-401 in Patients with Hyperlipidemia

THOMSON REUTERS

Cathie Wood’s ARK Investment buys 96K shares of Intellia Therapeutics today

Intellia Awards 44,450 Inducement RSUs to Eight New Employees Under 2024 Plan

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Beam Therapeutics (BEAM) Could Be 52% Undervalued Following Its Lawsuit Over Research Misuse

Simply Wall St.

Crispr Therapeutics Presents Phase 1 Zugo-Cel Data in Refractory Systemic Sclerosis at ACR Convergence 2026

CRISPR Therapeutics (CRSP) Stock May Command A Premium On Its Equity Base

Simply Wall St.

Intellia Therapeutics (NTLA), What Is Drawing Fresh Attention Now?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigermarketd.com/stock/BK4556/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4556","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":423.941,"timestamp":1791898694728,"preClose":432.49313,"halted":0,"volume":586444,"delay":0,"changeRate":-0.019774,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-8.552124,"latestTime":"10-13 09:38:17 EDT","open":430.89435,"high":430.89435,"low":421.3183,"amount":9137787.424062,"amplitude":0.022142,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791921600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":2.74401,"peRate":-9.892761,"turnoverRate":0.001342,"increases":0,"decrements":4,"flats":0,"marketCap":9568406400,"floatMarketCap":8970324768},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","high":430.89435,"amplitude":0.022142,"preClose":432.49313,"low":421.3183,"pbRate":"2.74401","latestPrice":424.17004,"volume":593507,"delay":0,"open":430.89435,"prevYearClose":431.70972,"prevWeekClose":446.961,"prevMonthClose":441.4069,"prevQuarterClose":441.4069,"fiveDayClose":442.1181,"twentyDayClose":416.5977,"sixtyDayClose":408.8835,"secType":"PLATE","market":"US","turnoverRate":0.001342,"peRate":-9.892761,"marketCap":9568406400,"floatMarketCap":8970324768,"timestamp":1791898697383,"nameCN":"Gene Editing"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4556\",,,,undefined,":{"bkCode":"BK4556","up":0,"down":4,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4556\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2675359113","title":"Intellia Therapeutics appoints Jing Marantz as chief medical officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2675359113","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675359113?lang=en_us&edition=fundamental","pubTime":"2026-10-13 19:36","pubTimestamp":1791891365,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics (NTLA) announced the appointment of Jing Marantz as executive VP and chief medical officer, effective October 26. Marantz wil...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/intellia-therapeutics-appoints-jing-marantz-as-chief-medical-officer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/intellia-therapeutics-appoints-jing-marantz-as-chief-medical-officer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4556","BK4585","LU1861559042.SGD","BK4139","LU1861558580.USD","BK4588","NTLA","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675356044","title":"Intellia Therapeutics Appoints Jing L. Marantz, M.d., Ph.d., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2675356044","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675356044?lang=en_us&edition=fundamental","pubTime":"2026-10-13 19:30","pubTimestamp":1791891002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261013:nTUAHZS6V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTLA","BK4588","BK4139","BK4556","LU1861558580.USD","BK4535","LU1861559042.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675535606","title":"Press Release: Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2675535606","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675535606?lang=en_us&edition=fundamental","pubTime":"2026-10-13 19:30","pubTimestamp":1791891000,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","BK4139","BK4535","NTLA","BK4232","BK4585","R","BK4588","BK4556","LU1861559042.SGD","BK4022","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675550733","title":"Beam Therapeutics Reports Initial Phase 1/2 Data for BEAM-301 in Glycogen Storage Disease Type Ia Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2675550733","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675550733?lang=en_us&edition=fundamental","pubTime":"2026-10-13 19:05","pubTimestamp":1791889545,"startTime":"0","endTime":"0","summary":"Beam Therapeutics reports initial Phase 1/2 data for BEAM-301 in glycogen storage disease type Ia trialBeam Therapeutics flagged initial Phase 1/2 results for BEAM-301 in glycogen storage disease type","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261013:nNDL17C6Bx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4585","BK4505","IE00BQXX3F31.USD","BK4112","BK4556","IE00BGHQF748.EUR","IE00BQXX3C00.GBP","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","BCDF","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2V16.EUR","BEAM","BK4611","LU1861558580.USD","SG9999014039.USD","BK4139","BK4535","IE00BQXX3D17.EUR","NDAQ","LU1861559042.SGD","LU0314104364.USD","SG9999014021.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","SG9999014005.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674883808","title":"Crispr Therapeutics General Counsel James R. Kasinger Disposes of 1,990 Common Shares Worth $119,481.19","url":"https://stock-news.laohu8.com/highlight/detail?id=2674883808","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674883808?lang=en_us&edition=fundamental","pubTime":"2026-10-09 05:35","pubTimestamp":1791495338,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics General Counsel James R. Kasinger disposes of 1,990 common shares worth $119,481.19James R. Kasinger, general counsel and secretary, exercised stock options for 1,990 common shares","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nNDL65MQgW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Crispr Therapeutics General Counsel James R. Kasinger Disposes of 1,990 Common Shares Worth $119,481.19","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","ARKG","BK4611","BK4556","BK4585","BK4139","LU1861559042.SGD","LU1861558580.USD","CRSP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673077189","title":"CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673077189","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673077189?lang=en_us&edition=fundamental","pubTime":"2026-10-08 20:30","pubTimestamp":1791462600,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland and BOSTON, Oct.  08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310, its investigational CRISPR/Cas9","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/08/3377269/0/en/crispr-therapeutics-to-present-late-breaking-data-at-the-american-heart-association-aha-scientific-sessions-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","LU1861558580.USD","AGT","IDNA","LU1861559042.SGD","BK4588","BK4107","ARKG","BK4117","BK4585","AFG","CRSP","SYNB","BK4139","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673607171","title":"Editas wins approval to launch EDIT-401 Strive trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2673607171","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673607171?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:28","pubTimestamp":1791458930,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Editas Medicine ( ($EDIT) ). On October 8, 2026, Editas Medicine said it had secured approval in Australia to b...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/editas-wins-approval-to-launch-edit-401-strive-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/editas-wins-approval-to-launch-edit-401-strive-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EDIT","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673939071","title":"Editas Medicine Receives Approval in Australia for Phase 3 Trial of EDIT-401 to Treat Hyperlipidemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2673939071","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673939071?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:28","pubTimestamp":1791458907,"startTime":"0","endTime":"0","summary":"Editas Medicine (EDIT) received approval in Australia to initiate the phase 1/2 Strive clinical trial of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia, the company said Thursday","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ZYAU.AU","GIVE.AU","EDIT","EIGA.AU","IOZ.AU","SLF.AU","IIGF.AU","BEAR.AU","VAP.AU","QRE.AU","DACE.AU","QFN.AU","XAO.AU","GEAR.AU","STW.AU","BBOZ.AU","BK4139","OZR.AU","IISV.AU","BK4556","IMLC.AU","E200.AU","VAS.AU","XKO.AU","XJO.AU","OZF.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673071338","title":"Editas Medicine receives approval to initiate clinical trial of EDIT-401","url":"https://stock-news.laohu8.com/highlight/detail?id=2673071338","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673071338?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:06","pubTimestamp":1791457602,"startTime":"0","endTime":"0","summary":"Editas Medicine (EDIT) announced it has received approval to initiate the Phase 1/2 Strive clinical trial of EDIT-401 in patients with Heterozygous...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/editas-medicine-receives-approval-to-initiate-clinical-trial-of-edit-401-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/editas-medicine-receives-approval-to-initiate-clinical-trial-of-edit-401-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","GDOC","NVIB","EDIT","IDNA","BK4139","BK4556","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673796050","title":"Editas Wins Australian Clearance to Start Phase 1/2 EDIT-401 Trial in HeFH Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2673796050","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673796050?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:02","pubTimestamp":1791457341,"startTime":"0","endTime":"0","summary":"Editas wins Australian clearance to start Phase 1/2 EDIT-401 trial in HeFH patientsEditas Medicine received Australian ethics clearance to start dosing in a Phase 1/2 trial of EDIT-401 for HeFH.The pr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nNDL8zwq0Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014021.USD","BK4112","IE00BQXX3D17.EUR","BK4556","BK4139","IE00BQXX3F31.USD","LU2095319765.USD","NDAQ","BK4588","IE00B64PRP62.GBP","LU0314104364.USD","LU2210149790.SGD","SG9999014013.SGD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","IE00BQXX3C00.GBP","IE00BN0W2V16.EUR","LU2210150020.SGD","BK4585","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","EDIT","IE00BN0W2T93.GBP","BCDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673507953","title":"Editas Medicine - Expects Topline Safety and Efficacy Data for Edit-401 Later in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2673507953","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673507953?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:00","pubTimestamp":1791457201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nTUA6S3VBJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EDIT","BK4556","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673079652","title":"Editas Medicine - to Begin Patient Dosing in 2026, Report Initial Data in Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2673079652","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673079652?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:00","pubTimestamp":1791457201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nTUA6S3VBJ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4556","BK4139","EDIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673007958","title":"Editas Medicine Receives Approval to Initiate First-in-Human Clinical Trial of Edit-401 in Patients with Hyperlipidemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2673007958","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673007958?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:00","pubTimestamp":1791457201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nTUA6S3VBJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4556","EDIT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673804290","title":"Cathie Wood’s ARK Investment buys 96K shares of Intellia Therapeutics today","url":"https://stock-news.laohu8.com/highlight/detail?id=2673804290","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673804290?lang=en_us&edition=fundamental","pubTime":"2026-10-06 08:25","pubTimestamp":1791246322,"startTime":"0","endTime":"0","summary":"20:23 EDT Cathie Wood’s ARK Investment buys 96K shares of Intellia Therapeutics (NTLA) today Published first on TheFly – the ultimate source for re...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-96k-shares-of-intellia-therapeutics-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-96k-shares-of-intellia-therapeutics-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARKX","LU1861559042.SGD","BK4585","BK4556","ARKF","SARK","BK4139","ARKK","NTLA","ARKW","BK4544","BK4588","LU1861558580.USD","BK4535","ARKQ","ARKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672746753","title":"Intellia Awards 44,450 Inducement RSUs to Eight New Employees Under 2024 Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2672746753","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672746753?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:01","pubTimestamp":1790971278,"startTime":"0","endTime":"0","summary":"Intellia awards 44,450 inducement RSUs to eight new employees under 2024 planIntellia Therapeutics awarded time-based restricted stock units covering 44,450 shares to eight new employees on Oct. 1, 20","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL2cxM6G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2095319765.USD","IE00BQXX3C00.GBP","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU1861558580.USD","LU1861559042.SGD","BK4585","BK4535","IE00BQXX3D17.EUR","BCDF","SG9999014039.USD","BK4588","SG9999014005.SGD","BK4112","BK4139","NDAQ","SG9999014013.SGD","LU0314104364.USD","BK4556","IE00BN0W2W23.USD","SG9999014021.USD","LU2210149790.SGD","IE00BQXX3F31.USD","NTLA","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672749913","title":"Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672749913","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672749913?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:01","pubTimestamp":1790971260,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Oct.  02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/02/3374008/0/en/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCLG","LU1861558580.USD","BK4585","BK4139","NTLA","BK4535","BK4556","LU1861559042.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672746319","title":"Beam Therapeutics (BEAM) Could Be 52% Undervalued Following Its Lawsuit Over Research Misuse","url":"https://stock-news.laohu8.com/highlight/detail?id=2672746319","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672746319?lang=en_us&edition=fundamental","pubTime":"2026-10-03 02:22","pubTimestamp":1790965349,"startTime":"0","endTime":"0","summary":"Beam Therapeutics (BEAM) is in the spotlight after filing a lawsuit that accuses former scientist Zi Jun Wang of misusing confidential research to help launch Chinese gene editing startup YolTech Therapeutics.\nFor investors watching Beam Therapeutics, the lawsuit lands after a stretch of weak momentum, with the share price down about 16% over 30 days and roughly 30% over 90 days. The 3 year total shareholder return is positive, while the 5 year total shareholder return remains deeply...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/beam-therapeutics-beam-could-be-52-undervalued-following-its","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/beam-therapeutics-beam-could-be-52-undervalued-following-its","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4611","BK4505","BK4588","BK4139","BK4556","BK4585","LU1861558580.USD","BK4535","LU1861559042.SGD","BEAM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672170057","title":"Crispr Therapeutics Presents Phase 1 Zugo-Cel Data in Refractory Systemic Sclerosis at ACR Convergence 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2672170057","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672170057?lang=en_us&edition=fundamental","pubTime":"2026-10-02 22:16","pubTimestamp":1790950565,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics presents Phase 1 zugo-cel data in refractory systemic sclerosis at ACR Convergence 2026CRISPR Therapeutics flagged Phase 1 clinical data for its CD19-targeting allogeneic CAR-T can","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDLbmv3d0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","LU2210150020.SGD","CRSP","LU1861558580.USD","BK4611","BCDF","BK4556","SG9999014039.USD","IE00BQXX3C00.GBP","BK4585","IE00BQXX3D17.EUR","BK4139","IE00BN0W2V16.EUR","LU0314104364.USD","SG9999014013.SGD","ARKG","IE00BGHQF748.EUR","LU1861559042.SGD","LU2210149790.SGD","LU2095319765.USD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","BK4112","IE00BKPKM429.USD","SG9999014005.SGD","IE00BQXX3F31.USD","NDAQ","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672962837","title":"CRISPR Therapeutics (CRSP) Stock May Command A Premium On Its Equity Base","url":"https://stock-news.laohu8.com/highlight/detail?id=2672962837","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672962837?lang=en_us&edition=fundamental","pubTime":"2026-10-02 09:19","pubTimestamp":1790903982,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics has delivered a mixed share price story over the past few years, and that uneven run puts fresh attention on what investors are really paying for on its balance sheet. With the stock now around US$55, the key issue is how that market value lines up against the company’s book value today.\n\nOver the past 5 years the share price has fallen 46.2%, which puts long term holders in focus and raises the question of whether the current valuation is still anchored to the underlying...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/crispr-therapeutics-crsp-stock-may-command-a-premium-on-its","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/crispr-therapeutics-crsp-stock-may-command-a-premium-on-its","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","EQR","BK4611","BK4215","LU1861558580.USD","BK4585","BK4588","CRSP","ARKG","LU1861559042.SGD","REZ","BK4556","SYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672590667","title":"Intellia Therapeutics (NTLA), What Is Drawing Fresh Attention Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2672590667","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672590667?lang=en_us&edition=fundamental","pubTime":"2026-10-01 18:17","pubTimestamp":1790849853,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics (NTLA) has stayed in focus after recent price moves, with the stock closing at US$12.06. Investors are weighing that level against the company’s clinical-stage CRISPR pipeline and collaboration footprint.\nFor context, the recent move around US$12.06 comes after a year where the share price return is up 30.94% year to date, but the 1 year total shareholder return has declined 41%, so momentum has picked up in the short term while longer term holders still face heavy...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-ntla-what-is-drawing-fresh-attention-n","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-ntla-what-is-drawing-fresh-attention-n","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4588","LU1861558580.USD","BK4585","LU1861559042.SGD","NTLA","BK4556","BK4535"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}]}}